VIDEO: Studies show better retinal fluid control with faricimab vs. aflibercept in DME
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Aleksandra V. Rachitskaya, MD, FASRS, discusses data that assessed time to retinal fluid control in diabetic macular edema treatment with faricimab vs. aflibercept.
The 2-year data were collected from the phase 3 YOSEMITE and RHINE studies.
“When we look at the 2 years in terms of intraretinal fluid, both faricimab arms controlled intraretinal fluid better than the aflibercept arm,” Rachitskaya said. “When we look at the time to intraretinal fluid control, we saw that it happened faster in the faricimab arms.”
Collapse
Rachitskaya AV. Time to retinal fluid control with faricimab vs aflibercept in patients with DME in the phase 3 YOSEMITE/RHINE trials. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about
Click Here to Manage Email Alerts